High-dose chemotherapy and autologous stem cell transplant in adolescent patients with relapsed or refractory Hodgkin's lymphoma

Bone Marrow Transplantation

Volumn 45, Issue 3, 2010, Pages 476-482

  Akhtar, S ^a   El Weshi, A ^b   Rahal, M ^c   Abdelsalam, M ^a   Al Husseini, H ^a   Maghfoor, I ^a  

^a KING FAISAL SPECIALIST HOSPITAL AND RESEARCH CENTER   (Saudi Arabia)

^b Centre Hospitalier Public du Cotentin   (France)

^c KING FAHAD SPECIALIST HOSPITAL   (Saudi Arabia)

Author keywords

Adolescent; ESHAP chemotherapy; Hodgkin's lymphoma; Prognostic factors; SCT

Indexed keywords

BLEOMYCIN; CARMUSTINE; CHLORMETHINE; CISPLATIN; CYCLOPHOSPHAMIDE; CYTARABINE; DACARBAZINE; DOXORUBICIN; ETOPOSIDE; GRANULOCYTE COLONY STIMULATING FACTOR; MELPHALAN; METHYLPREDNISOLONE SODIUM SUCCINATE; PREDNISONE; PROCARBAZINE; VINBLASTINE; VINCRISTINE;

ADOLESCENT; ADULT; ARTICLE; AUTOLOGOUS STEM CELL TRANSPLANTATION; CANCER COMBINATION CHEMOTHERAPY; CANCER REGRESSION; CANCER RELAPSE; EVENT FREE SURVIVAL; FEMALE; FOLLOW UP; HODGKIN DISEASE; HUMAN; MAJOR CLINICAL STUDY; MALE; MORTALITY; OVERALL SURVIVAL; PRIORITY JOURNAL; PROBABILITY; PROGNOSIS; SALVAGE THERAPY; TREATMENT RESPONSE;

ADOLESCENT; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; COHORT STUDIES; COMBINED MODALITY THERAPY; DISEASE-FREE SURVIVAL; FEMALE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HODGKIN DISEASE; HUMANS; KAPLAN-MEIERS ESTIMATE; MALE; PROGNOSIS; RETROSPECTIVE STUDIES; SALVAGE THERAPY; TRANSPLANTATION, AUTOLOGOUS; YOUNG ADULT;

EID: 77949425399     PISSN: 02683369     EISSN: 14765365     Source Type: Journal    
DOI: 10.1038/bmt.2009.197     Document Type: Article

References (32)

1. Foltz L, Song K, Connors J. Hodgkin's lymphoma in adolescents. J Clin Oncol 2006; 24: 2520-2526.
2. Canellos G, Anderson J, Propert K, Nissen N, Cooper M, Henderson E et al. Chemotherapy for advanced Hodgkin's disease with MOPP, ABVD, or MOPP alternating with ABVD. N Engl J Med 1992; 327: 1478-1484.
3. Linch D, Winfield D, Goldstone A, Moir D, Hancock B, McMillan A et al. Dose intensification with autologous bonemarrow transplantation in relpased and resistant Hodgkin's disease: results of a BNLI randomised trial. Lancet 1993; 341: 1051-1054.
4. Schmitz N, Pfistner B, Sextro M, Sieber M, Carella AM, Haenel M et al. Aggressive conventional chemotherapy compared with high-dose chemotherapy with autologous haemopoietic stem-cell transplantation for relapsed chemosensitive Hodgkin's disease: a randomised trial. Lancet 2002; 359: 2065-2071.
5. Longo D, Duffey P, Young R, Hubbard S, Ihde D, Glatstein E et al. Conventional-dose salvage combination chemotherapy in patients relapsing with Hodgkin's disease after combination chemotherapy: the low probability for cure. J Clin Oncol 1992; 10: 210-218.
6. Bonfante V, Santoro A, Viviani S, Devizzi L, Balzarotti M, Soncini F et al. Outcome of patients with Hodgkin's disease failing after primary MOPP-ABVD. J Clin Oncol 1997; 15: 528-534.
7. Chopra R, McMillan AK, Linch DC, Yuklea S, Taghipour G, Pearce R et al. The place of high-dose BEAM therapy and autologous bone marrow transplantation in poor-risk Hodgkin's disease. A single-center eight-year study of 155 patients. Blood 1993; 81: 1137-1145.
8. Bierman PJ, Vose JM, Armitage JO. Autologous transplantation for Hodgkin's disease: coming of age? Blood 1994; 83: 1161-1164.
9. Reece DE, Barnett MJ, Shepherd JD, Hogge DE, Klasa RJ, Nantel SH et al. High-dose cyclophosphamide, carmustine (BCNU), and etoposide (VP16-213) with or without cisplatin (CBV +/- P) and autologous transplantation for patients with Hodgkin's disease who fail to enter a complete remission after combination chemotherapy. Blood 1995; 86: 451-456.
10. Horning SJ, Chao NJ, Negrin RS, Hoppe RT, Long GD, Hu WW et al. High-dose therapy and autologous hematopoietic progenitor cell transplantation for recurrent or refractory Hodgkin's disease: analysis of the Stanford University results and prognostic indices. Blood 1997; 89: 801-813.
11. Lazarus HM, Rowlings PA, Zhang MJ, Vose JM, Armitage JO, Bierman PJ et al. Autotransplants for Hodgkin's disease in patients never achieving remission: a report from the Autologous Blood and Marrow Transplant Registry. J Clin Oncol 1999; 17: 534-545.
12. André M, Henry-Amar M, Pico JL, Brice P, Blaise D, Kuentz M et al. Comparison of high-dose therapy and autologous stem-cell transplantation with conventional therapy for Hodgkin's disease induction failure: a case-control study. Socié té Francaise de Greffe de Moelle. J Clin Oncol 1999; 17: 222-229.
13. Sweetenham JW, Carella AM, Taghipour G, Cunningham D, Marcus R, Della Volpe A et al. High-dose therapy and autologous stem-cell transplantation for adult patients with Hodgkin's disease who do not enter remission after induction chemotherapy: results in 175 patients reported to the European Group for Blood and Marrow Transplantation. Lymphoma Working Party. J Clin Oncol 1999; 17: 3101-3109.
14. Josting A, Rueffer U, Franklin J, Sieber M, Diehl V, Engert A. Prognostic factors and treatment outcome in primary progressive Hodgkin lymphoma: a report from the German Hodgkin Lymphoma Study Group. Blood 2000; 96: 1280-1286.
15. Sureda A, Arranz R, Iriondo A, Carreras E, Lahuerta JJ, García-Conde J et al. Autologous stem-cell transplantation for Hodgkin's disease: results and prognostic factors in 494 patients from the Grupo Español de Linfomas/Transplante Autó logo de Médula Osea Spanish Cooperative Group. J Clin Oncol 2001; 19: 1395-1404.
16. Fermé C, Mounier N, Diviné M, Brice P, Stamatoullas A, Reman O et al. Intensive salvage therapy with high-dose chemotherapy for patients with advanced Hodgkin's disease in relapse or failure after initial chemotherapy: results of the Groupe d'Etudes des Lymphomes de l'Adulte H89 Trial. J Clin Oncol 2002; 20: 467-475.
17. Czyz J, Szydlo R, Knopinska-Posluszny W, Hellmann A, Gozdzik J, Hansz J et al. Treatment for primary refractory Hodgkin's disease: a comparison of high-dose chemotherapy followed by ASCT with conventional therapy. Bone Marrow Transplant 2004; 33: 1225-1229.
18. Moskowitz CH, Kewalramani T, Nimer SD, Gonzalez M, Zelenetz AD, Yahalom J. Effectiveness of high dose chemoradiotherapy and autologous stem cell transplantation for patients with biopsy-proven primary refractory Hodgkin's disease. Br J Haematol 2004; 124: 645-652.
19. Lavoie JC, Connors JM, Phillips GL, Reece DE, Barnett MJ, Forrest DL et al. High-dose chemotherapy and autologous stem cell transplantation for primary refractory or relapsed Hodgkin lymphoma: long-term outcome in the first 100 patients treated in Vancouver. Blood 2005; 106: 1473-1478.
20. Morabito F, Stelitano C, Luminari S, Mammi C, Marcheselli L, Callea V et al. The role of high-dose therapy and autologous stem cell transplantation in patients with primary refractory Hodgkin's lymphoma: a report from the Gruppo Italiano per lo Studio dei Linfomi (GISL). Bone Marrow Transplant 2006; 37: 283-288.
21. Williams CD, Goldstone AH, Pearce RG, Green S, Armitage JO, Carella A et al. Autologous bone marrow transplantation for pediatric Hodgkin's disease: a case-matched comparison with adult patients by the European Bone Marrow Transplant Group Lymphoma Registry. J Clin Oncol 1993; 11: 2243-2249.
22. Baker KS, Gordon BG, Gross TG, Abromowitch MA, Lyden ERL, Lynch JC et al. Autologous hematopoietic stem-cell transplantation for relapsed or refractory Hodgkin's disease in children and adolescents. J Clin Oncol 1999; 17: 825-831.
23. Verdeguer A, Pardo N, Madero L, Martinez A, Bureo E, Fernandez JM et al. Autologous stem cell transplantation for advanced Hodgkin's disease in children. Spanish group for BMT in children (GETMON), Spain. Bone Marrow Transplant 2000; 25: 31-34.
24. Kobrinsky NL, Sposto R, Shah NR, Anderson JR, DeLaat C, Morse M et al. Outcomes of treatment of children and adolescents with recurrent non-Hodgkin's lymphoma and Hodgkin's disease with dexamethasone, etoposide, cisplatin, cytarabine, and l-asparaginase, maintenance chemotherapy, and transplantation: Children's Cancer Group Study CCG- 5912. J Clin Oncol 2001; 19: 2390-2396.
25. Lieskovsky YE, Donaldson SS, Torres MA, Wong RM, Amylon MD, Link MP et al. High-dose therapy and autologous hematopoietic stem-cell transplantation for recurrent or refractory pediatric Hodgkin's disease: results and prognostic indices. J Clin Oncol 2004; 22: 4532-4540.
26. Schellong G, Dö rffel W, Claviez A, Kö rholz D, Mann G, Scheel-Walter H et al. Salvage therapy of progressive and recurrent Hodgkin's disease: results from a multicenter study of the pediatric DAL/GPOH-HD study group. J Clin Oncol 2005; 23: 6181-6189.
27. Petropoulos D, Worth L, Mullen C, Lockhart S, Choroszy M, Chan K. Interferon-alpha after autologous stem cell transplantation in pediatric patients with advanced Hodgkin's lymphoma. Bone Marrow Transplant 2006; 38: 345-349.
28. Akhtar S, Tbakhi A, Humaidan H, El Weshi A, Rahal M, Maghfoor I. ESHAP + fixed dose G-CSF as autologous peripheral blood stem cell mobilization regimen in patients with relapsed or refractory diffuse large cell and Hodgkin's lymphoma: a single institution result of 127 patients. Bone Marrow Transplant 2006; 37: 277-282.
29. Hasenclever D, Diehl V. A prognostic score for advanced Hodgkin's disease. International Prognostic Factors Project on Advanced Hodgkin's Disease. N Engl J Med 1998; 339: 1506-1514.
30. Sureda A, Constans M, Iriondo A, Arranz R, Caballero MD, Vidal MJ et al. Prognostic factors affecting long-term outcome after stem cell transplantation in Hodgkin's lymphoma autografted after a first relapse. Ann Oncol 2005; 16: 625-633.
31. Czyz J, Hellmann A, Dziadziuszko R, Hansz J, Gozdzik J, Holowiecki J et al. High-dose chemotherapy with autologous stem cell transplantation is an effective treatment of primary refractory Hodgkin's disease. Retrospective study of the Polish Lymphoma Research Group. Bone Marrow Transplant 2002; 30: 29-34.
32. Yuen AR, Rosenberg SA, Hoppe RT, Halpern JD, Horning SJ. Comparison between conventional salvage therapy and high-dose therapy with autografting for recurrent or refractory Hodgkin's disease. Blood 1997; 89: 814-822.